Neurotransmission and pharmacokinetics after cannabis administration
Conditions
Interventions
300 microg/kg bodyweight THC and placebo
Sponsors
University of Maastricht
Eligibility
Inclusion criteria
Inclusion criteria: Occasional users (N=20): Used cannabis between 1 times a month and 1 times a week during the previous year Chronic users (N=20): Used cannabis more than 3 times a week during the previous year • Age between 18 and 40 years • Free from psychotropic medication • Good physical health as determined by medical examination and laboratory analysis • Absence of any major medical, endocrine and neurological condition • Normal weight, body mass index (weight/height2) between 18 and 28 kg/m2 • Written Informed Consent • Good knowledge and understanding of the Dutch language
Exclusion criteria
Exclusion criteria: • History of drug abuse (other than the use of cannabis) or addiction (determined by the medical questionnaire, drug questionnaire and medical examination) • Pregnancy or lactation • Hypertension (diastolic> 90; systolic> 140) • Current or history of psychiatric disorder (determined by the medical questionnaire and medical examination) • Liver dysfunction • (Serious) side effects to previous cannabis • History of cardiac dysfunctions (arrhythmia, ischemic heart disease,…) • For women: no use of a reliable contraceptive
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neurotransmission of glutamate, GABA and dopamine will be assessed using MRS and resting state fMRI. | — |
Secondary
| Measure | Time frame |
|---|---|
| THC kinetics in blood, subjective experiences of drug, and cognitive performance | — |
Contacts
Public ContactE.L. Theunissen
Maastricht University
Outcome results
None listed